Issue link: https://viewer.e-digitaledition.com/i/1160072
SCIENTISTS AT THE CRNIC INSTITUTE Publish First Cases of Immunotherapy for Alopecia Areata in People with Down Syndrome RESEARCHERS AND DOCTORS at the Linda Crnic Institute for Down Syndrome, the University of Colorado Department of Dermatology, and the Palo Alto Medical Foundation in California have just published the first report of safe and efficacious use of an immune modulatory strategy to treat alopecia areata in individuals with Down syndrome. The drug featured in the publication is tofacitinib, sold under the brand name Xeljanz, which belongs to a class of drugs known as JAK inhibitors. The results in this publication hold promise not only for the treatment of alopecia areata but could possibly hold the key for other autoimmune disorders and ailments found in people with Down syndrome. This research builds upon the Crnic Institute's groundbreaking discovery that people with Down syndrome have profound immune system dysregulation and autoimmunity associated with chronic activation of a branch of the immune system known as the interferon response. Alopecia areata is an autoimmune disorder in which the immune system mistakenly attacks the hair follicles, causing hair loss. People with Down syndrome have up to a 10-fold higher risk of developing alopecia areata than the typical population, as well as increased risk of developing many other immune disorders. The research team studied how Xeljanz impacted two individuals with Down syndrome who have alopecia areata. The scientists discovered a remarkable recovery of hair growth within weeks of beginning treatment with no measurable side effects. The study results were published on April 5 in the Journal of the American Association of Dermatology Case Reports. "For the past four years, we have been hypothesizing that partially inhibiting the interferon response with specific drugs would have therapeutic benefits for people with Down syndrome, and these two cases clearly support our hypothesis," says Joaquín Espinosa, Ph.D., Executive Director of the Crnic Institute, an affiliate of the Global Down Syndrome Foundation. Dr. Espinosa and several expert scientists at the Crnic Institute believe that Xeljanz could have a wide range of positive effects on a variety of health issues and the overall well-being of people with Down syndrome. Xeljanz is manufactured by Pfizer Inc. and approved in the United States for use in other autoimmune disorders THE RESEARCH OFFERS A POTENTIAL PATHWAY TO NORMALIZING THE LARGER PROBLEM OF IMMUNE SYSTEM DYSREGULATION. 2019 ISSUE 2 OF 4 • DOWN SYNDROME WORLD ™ 8

